Background: The cardiotoxicity of adriamycin limits its clinical usefulness as a powerful drug for solid tumors and malignant hematological disease. Although the exact mechanism by which it causes cardiac damage is not yet known, several reports have suggested apoptosis to be the principal process in adriamycin-induced cardiomyopathy, which exhibits DNA fragmentation, cytochrome C release, and caspase activation. However, no direct evidence has linked the critical involvement of caspase-3 in adriamycin-induced apoptosis. Methods: To determine the requirements for the activation of caspase-3 in adriamycin-treated cardiac cells, we examined the effect of caspase inhibitor on the cell survival and apoptotic changes, using MTT assay, microscopy and Western blotting. Results: Exposure of H9c2 cells to adriamycin resulted in time-and dose-dependent cell death and cleavage of pro-caspase-3 and the nuclear protein poly (ADP-ribose) polymerase (PARP). However, neither the reduction of cell viability nor the characteristic morphological changes induced by adriamycin was prevented by pretreatment with the general caspase inhibitor z-VAD.FMK. In contrast, caspase inhibition effectively blocked the apoptosis induced by H 2 O 2 in H9c2 cells, but was not essential for adriamycin-induced apoptosis in H9c2 cells. We also observed that p53 expression was increased by adriamycin, and this increase was not affected by the inhibition of caspase activity, suggesting a role for p53 in adriamycin-induced caspase-independent apoptosis in cardiac toxicity. Conclusions: Our results demonstrate that adriamycin specifically activates an apoptotic pathway that is not dependent upon the activation of caspase. (Korean Circulation J 2004 ; 34 (1) : 76-83) 
Introduction
Adriamycin is a powerful chemotherapeutic agent for solid tumors and malignant hematological disease. However, cardiac toxicity, including the development of cardiomyopathy and, ultimately, congestive heart failure, limits the clinical usefulness of the drug. 1) Therefore, identifying the mechanisms that underlie adriamycininduced cardiac damage is essential to developing strategies to interrupt the cardiotoxic action of adriamycin. Several hypotheses have been proposed to account for adriamycin cardiotoxicity, including the generation of free radicals, impaired adrenergic regulation, release of vasoactive amines, changed calcium handling, mitochondrial dysfunction, suppression of muscle-specific genes, and ceramide generation. [2] [3] [4] [5] [6] [7] [8] [9] The length of this list indicates that the molecular mechanisms leading to adriamycin-induced cardiomyopathy are not yet clearly understood. Recent studies have shown that apoptosis is one of the major processes leading to the progressive deterioration of myocardial function induced by adriamycin. In isolated adult rat cardiac myocytes, treatment with adriamycin resulted in DNA fragmentation, chromatin condensation, and nuclear shrinkage-all of which are classical features of apoptosis. 10) Despite increasing evidence of the occurrence of apoptosis, the apoptotic signaling pathway activated by adriamycin in cardiac cells still remains to be elucidated. A common and critical event in the execution of apoptosis is the activation of a group of cysteine proteases called caspases. 11) At least 14 distinct caspases have so far been cloned and divided into two groups, the initiator and effector caspases, according to their functions during the apoptotic process. 12) Of these, caspase-3 is the main effector caspase and cleaves the DEVD motif of many cellular substrates, inducing the fundamental features of apoptotic cell death. 13) Adriamycin also increases cytochrome c efflux, which is a representative caspase activator, in rat heart mitochondria. 14) Moreover, caspase-3 activity increases when adriamycin is administered to the H9c2 rat cardiac myocyte cell line, as determined using a fluorogenic substrate. 10) Although these findings suggest that the activation of caspase might be involved in adriamycininduced apoptosis in cardiac myocytes, it is still possible that the processing of caspase-3 is an accompanying or subsequent event after apoptosis has been triggered, rather than a critical requirement for the induction of apoptosis.
Therefore, to determine whether caspase activation is necessary for adriamycin-induced apoptosis in H9c2 rat cardiac myocyte cells, we examined the effects of caspase inhibition, using the general caspase inhibitor z-VAD.FMK in effective concentrations, on the survival of and morphological changes in H9c2 cells exposed to adriamycin.
We describe here that caspase activation is not essential for the death of cardiac cells caused by adriamycin. A possible role for p53 in the caspase-independent apoptosis induced by adriamycin is briefly discussed.
Methods

Chemicals and antibodies
Adriamycin (Doxorubicin) and MTT (2-(4,5-dimethyltriazol-2-yl)-2,5-diphenyl tetrazolium bromide) were purchased from Sigma Chemical Co (ST. Lous, MO, USA). Caspase-3 colorimetric assay kit (Cat. No. 
Cell cultures and adriamycin treatment
The cardiac muscle cell line H9c2 was obtained from American Type Culture Collection (ATCC). The cells were maintained at 37℃ in a 5% CO 2 humidified atmosphere in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum and antibiotic solutions (100 Units/mL of penicillin and 100 μg/mL streptomycin) (Gibco-BRL, NY, USA). Cells were subcultured at a 1：4 ratio every 3 days.
Cell viability analysis
Cell viability was monitored by the classical MTT assay. Briefly, 50 μL of the MTT reagent (final concentration: 500 μg/mL) was added to each well. Three hours later at 37℃, the cell supernatants were discarded, MTT crystals were dissolved with acid isopropanol, and absorbance was measured at 570 nm. All assays were performed in triplicate, and data were presented as average±SEM value. Percent of viability was defined as relative absorbance of treated versus untreated control cells.
Analysis of nuclear morphology
Cells were plated in 6 well chamber slides and were allowed to adhere. Adriamycintreated and untreated cells were fixed with methanol: acetic acid=3：1 (v/v) for totic cells were defined on the basis of nuclear changes, such as chromatin condensation and fragmentation.
Caspase-3 activation assay
Caspase-3 activity was measured with an ApoAlert 
Immunoblot analysis
Adriamycin-treated cells were harvested and lysed in ice-cold RIPA buffer (50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate). Equivalent protein extracts from each sample were separated by 12.5% SDS-PAGE. Proteins were transferred onto PVDF membranes (Immobilon-P, Milipore, Bedford, USA). The membranes were blocked with PBS containing 5% nonfat milk and incubated for 1h at room temperature with primary antibodies (1/500). The blots were washed four times for 15 min with 0.3% Tween 20-containing PBS and incubated for 1 h with peroxidase-labeled anti-mouse or anti-rabbit immunoglobulin (1/5000). The membrane was washed again four times. The blots were developed using an enhanced chemiluminescence detection system (ECL, Amersham Corp., Cardiff, UK).
Results
As previously described, exposure to adriamycin resulted in dose-and time-dependent toxicity in H9c2 cells ( Figure 1A) . The reduction in cell viability was Figure 1 . Adriamycin induces apoptosis in H9c2. A: H9c2 cells were treated with various concentrations of adriamycin for the indicated times, and cell viability was measured by MTT assay. Relative cell viability was determined as a percentage of viability at 0 h, which was adjusted to 100%. The displayed values are the means ±S.D of three independent experiments. B: proteolytic cleavage of PARP was shown during the time course of adriamycin-induced apoptosis. H9c2 cells were treated with 1 μM of adriamycin for various time periods and analyzed by Western blotting using anti-PARP antibody. 113 kD PARP protein was specifically cleaved into 89 kD fragment. C: adriamycin led decrease in procaspase-3 from each time point. H9c2 cells were treated with 1 μM of adriamycin. Cell lysates were analyzed for Western blotting using anti-caspase-3 antibody. β-Actin level was also examined as a loading control. Figure 3B ). These characteristics were also detected in cells pretreated with the caspase inhibitor ( Figure 3C ). However, in agreement with the cell-death assay, z-VAD.FMK prevented the morphological changes induced by H 2 O 2 ( Figure 3E, F) . Our results, taken together, strongly suggest that, although caspase activation occurs in H9c2 cells after adriamycin treatment, as observed in this study and by other investigators, the activation of caspase is not an essential step in the promotion of apoptosis by adriamycin in these cells. Therefore, a caspase-independent pathway might be the main effector downstream from adriamycin that leads H9c2 cells into apoptotic cell death.
A recent report indicated p53 to regulate apoptosis without any involvement of the caspase family.
16) Furthermore, adriamycin was reported to induce p53 expression in many cell types. 17)18) Therefore, to evaluate Figure 4A ). Time-course analysis revealed that the induction of p53 was detectable as early as 6 h after treatment with 1 μM of adriamycin. This increase was maintained for up to 48 h after treatment and was not prevented by pretreatment with the caspase inhibitor ( Figure 4B ). These findings raise the possibility that p53 participates as a key molecule in the adriamycininduced apoptotic pathway, which is not dependent upon the activation of caspase.
Discussion
Apoptosis has been regarded as one of the mechanisms underlying the cardiotoxic effects of adriamycin. This is supported by the fact that several typical apoptotic features, including mitochondrial dysfunction, DNA fragmentation, and caspase activation, are induced by adriamycin in the H9c2 rat cardiac myocyte cell line, which is used as a model for adriamycin-induced cardiac toxicity. 19) Recently, an insulin-like growth factor I (IGF-1) was shown to inhibit the apoptosis induced by adriamycin in H9c2 cells, concomitant with attenuating caspase 3 activation, suggesting caspase-3 activation as the cause of cell death in adriamycin-induced apoptosis. 10) In this investigation, we also observed, by western blotting, that caspase-3 activation occurred during adriamycin-induced apoptosis, as revealed by a decrease in procaspase-3 and the processing of the nuclear protein PARP, a well-known substrate of caspase-3-like activity,
and by an increase in DEVD-cleaving activity. However, caspase inhibition had no effect on the survival of H9c2 Recently, it has been reported that several stimuli, such as chloroquine, camptothecin, low concentrations of nitric oxide, and potassium depletion, induce apoptosis without the involvement of caspase activation. 20) Bcl-2 family proteins or the p53 protein seem to regulate some caspase-independent apoptotic processes. 21) Our results
show that p53 expression was induced by adriamycin in H9c2 cells, and that this was not affected by the caspase inhibitor, implying a role for p53 as a key molecule in caspase-independent apoptosis. Furthermore, exposure of H9c2 cells to adriamycin or hypoxia increases the expression of Bax, a downstream effector of p53, and this cates to the nucleus, where it binds to DNA and induces caspase-independent chromatin condensation. 27) However, further studies using a system in which p53 expression is specifically regulated are required to define the exact role of p53 and its downstream pathway in the caspaseindependent apoptosis induced by adriamycin.
The generation of reactive oxygen species (ROS) has been implicated as one mechanism involved in adriamycin-induced cardiotoxicity. 28) Because H 2 O 2 , which generates ROS, induces apoptosis via a caspase-dependent pathway, as shown in our results, and because ROS mediate adriamycin-induced apoptosis in the absence of p53 in Saos-2 cells, 29) adriamycin probably induces apoptosis via two different pathways. One is a caspaseindependent but p53-dependent pathway, and the other a caspase-dependent but p53-independent pathway, which involves the generation of ROS. Of these, the former seems to predominate in H9c2 cells, based on the results presented in this study. Therefore, a more extensive investigation of the molecular mechanisms of the caspaseindependent pathway induced by adriamycin will provide useful information for developing pharmacological agents, other than caspase inhibitors, that interfere with the progression of cardiotoxicity when adriamycin is used in anti-cancer therapy.
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